retatrutide cause cancer Incretin triple agonist (LY3437943) alleviates obesity-associated progression Incretin triple agonist retatrutide (LY3437943)
Description
Learn how GLP-1 can help
Safety issues like the black box warning for thyroid cancer risk are also addressed
With demand skyrocketing, are consumers unknowingly risking their health
Mohsin SN, Saleem F, Humayun A, Tanweer A, Muddassir A
Retatrutide is a next-generation synthetic peptide acting as a triple receptor agonist, simultaneously targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors
Expert prescribers sharing evidence-based weight loss guidance.
